BioSpace News Archive

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2021

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following virtual conferences in May

Agiliti Inc. (NYSE: AGTI) (“Agiliti”) today announced that the company will release its first quarter results after the market close on Tuesday, May 18, 2021, to be followed by a conference call at 5:00 p.m. (Eastern Time) on the same day.

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that the Company will report its first quarter 2021 financial results and provide a corporate update on Tuesday, May 11, 2021.

Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter solutions developed on a robust intellectual property platform, designed to connect People and Things, today announced that management will participate in the Oppenheimer 6th Annual Emerging Growth Conference taking place virtually May 11-12, 2021.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events:

BofA Securities 2021 Health Care Conference Fireside Chat Presentation: Wednesday, May 12, 2021 at 2:45 p.m. Eastern Time.

The Company sees increased technology usage across its installed base and anticipates enrolling to at least 1500 cases by the end of 2021

MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today urged shareholders to consider several key questions about Prescience Point’s interests, motivations and actions regarding the disruptive proxy fight it is waging to gain undue influence over the MIMEDX Board of Directors

Releviate™ Therapeutics, a bio-pharmaceutical company addressing the needs of patients suffering from neuropathic pain, today welcomes Jennifer Maynard to its scientific advisory board.